The recent developments in "sexual pharmacology" only reinforced some to warn us about the medicalization of sexual dysfunction and human sexuality in general. We believe that the treatment of sexual dysfunctions/disorders belongs to the realm of medicine. However, we also believe that the "sexual pharmacology" and total medicalization of sexuality does not provide the best understanding of the complexities of human sexuality and is not always in the best interest of our patients.
Bancroft among others cautions just about a few important issues connected to medicalization of human sexuality. He points out that male sexuality has been medicalized for most of the 20th century, and that medical profession has paid more attention to female sexuality lately (interestingly, this increased interest seems to parallel with the increased interest of the pharmaceutical industry in female sexuality).
Bancroft points out that the interface between psychological processes and physiological response, especially in women, is not well understood. He discusses the numerous male-female differences in sexuality. He also asks, "when is a sexual problem a sexual dysfunction," as many times impaired sexual interest or response in women is psychologically understandable and thus rather an adaptive response to a problem in the sexual relationship rather than sexual dysfunction.
Medicalization of sexual dysfunction and human sexuality has been beneficial to some extent in expanding part of our understanding of human sexuality and its impairment(s), and in expanding our treatment armamentarium. However, it also poses dangers in a form of trivialization of human sexuality and secondary suppression of exploring other avenues of our understanding of human sexuality.
Conclusion
From the discussion of the history of the field, the evolution of nomenclature, and emerging data on epidemiology, it is clear that this is a field in rapid evolution. Most of the impetus for this change came from the discovery of effective oral therapies for male sexual disorder and the subsequent search for similar therapies for women. This has contributed to better studies of the epidemiology of these disorders and to debates about the proper nomenclature. In addition, clinicians have begun trying to find which psychological, pharmacological, or combined approach is most suited to treat these disorders.
The purpose of this book was to assemble experts in treatment of each disorder into one text so that this text could serve as a treatment guide for students and practicing clinicians. Ultimately, we hope that those who will benefit the most are our patients. Patient sexual satisfaction may be associated with many health factors, including a reduced risk for subsequent new severe disabilities.
Bancroft among others cautions just about a few important issues connected to medicalization of human sexuality. He points out that male sexuality has been medicalized for most of the 20th century, and that medical profession has paid more attention to female sexuality lately (interestingly, this increased interest seems to parallel with the increased interest of the pharmaceutical industry in female sexuality).
Bancroft points out that the interface between psychological processes and physiological response, especially in women, is not well understood. He discusses the numerous male-female differences in sexuality. He also asks, "when is a sexual problem a sexual dysfunction," as many times impaired sexual interest or response in women is psychologically understandable and thus rather an adaptive response to a problem in the sexual relationship rather than sexual dysfunction.
Medicalization of sexual dysfunction and human sexuality has been beneficial to some extent in expanding part of our understanding of human sexuality and its impairment(s), and in expanding our treatment armamentarium. However, it also poses dangers in a form of trivialization of human sexuality and secondary suppression of exploring other avenues of our understanding of human sexuality.
Conclusion
From the discussion of the history of the field, the evolution of nomenclature, and emerging data on epidemiology, it is clear that this is a field in rapid evolution. Most of the impetus for this change came from the discovery of effective oral therapies for male sexual disorder and the subsequent search for similar therapies for women. This has contributed to better studies of the epidemiology of these disorders and to debates about the proper nomenclature. In addition, clinicians have begun trying to find which psychological, pharmacological, or combined approach is most suited to treat these disorders.
The purpose of this book was to assemble experts in treatment of each disorder into one text so that this text could serve as a treatment guide for students and practicing clinicians. Ultimately, we hope that those who will benefit the most are our patients. Patient sexual satisfaction may be associated with many health factors, including a reduced risk for subsequent new severe disabilities.
About The Author
David Crawford is the CEO and owner of a penis extenders company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of erectile problems in men This article may be freely distributed if this resource box stays attached.
Article Source: http://EzineArticles.com/?expert=David_A_Crawford David Crawford is the CEO and owner of a penis extenders company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of erectile problems in men This article may be freely distributed if this resource box stays attached.
No comments:
Post a Comment